AMR Action Fund CEO Henry Skinner participated in a wide-ranging Q&A with European Biotech that touched on the market challenges antimicrobial developers face and the global landscape of antibiotic innovation.
“What really concerns me is that in the absence of a viable market, all of the early-stage grant funding and R&D will be for naught. There is an adage that 'you can’t push a rope,' and this applies to financing innovation to address the issues of antimicrobial resistance,” Dr. Skinner said. He added, “If Europe can get the right pull incentives in place, I think it would send a strong message to investors and give an advantage to the small antimicrobial companies that are doing very good work and leading innovation across Europe.”
Read the full interview here.
